Pupillary responses in non-proliferative diabetic retinopathy.
Park JC, Chen YF, Blair NP, Chau FY, Lim JI, Leiderman YI, Shahidi M, McAnany JJ.
Sci Rep. 2017 Mar 23;7:44987. doi: 10.1038/srep44987.
PMID:28332564
The unmet need for better risk stratification of non-proliferative diabetic retinopathy.
Sivaprasad S, Pearce E.
Diabet Med. 2019 Apr;36(4):424-433. doi: 10.1111/dme.13868. Epub 2018 Dec 7.
PMID:30474144
The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials.
Liu Z, Chen Y, Jie C, Wang J, Deng Y, Hou X, Li Y, Cai W.
Front Endocrinol (Lausanne). 2023 Apr 3;14:1144290. doi: 10.3389/fendo.2023.1144290. eCollection 2023.
PMID:37077355
Effect of Chinese Patent Medicines on Ocular Fundus Signs and Vision in Calcium Dobesilate-Treated Persons With Non-Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
Zhang Y, An X, Duan L, Jin D, Duan Y, Zhou R, Zhang Y, Kang X, Lian F.
Front Endocrinol (Lausanne). 2022 Mar 14;13:799337. doi: 10.3389/fendo.2022.799337. eCollection 2022.
PMID:35370950
Proliferative diabetic retinopathy detection: Comparison of clinical examination, optomap photographs and fluorescein angiography.